Precision cancer therapies: Where are we?
Drug Discovery World
MARCH 2, 2023
Positive early signs for precision cancer therapies In the first presentation, Dr Fiona McLaughlin, CSO, provided an update on Avacta’s oncology candidates that are currently in clinical development. She explained the mechanism by which AVA6000 can provide more precise treatment than current chemotherapies.
Let's personalize your content